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Background: To assess the diagnostic value of retrospective PET-MRI fusion and to compare the results with
side-by-side analysis and single modality use of PET and of MRI alone for locoregional tumour and nodal staging of
head-and-neck cancer.
Methods: Thirty-three patients with head-and-neck cancer underwent preoperative contrast-enhanced MRI and PET/
CT for staging. The diagnostic data of MRI, PET, side-by-side analysis of MRI and PET images and retrospective PET-MRI
fusion were systematically analysed for tumour and lymph node staging using receiver operating characteristic (ROC)
analysis. The results were correlated to the histopathological evaluation.
Results: The overall sensitivity/specificity for tumour staging for MRI, PET, side-by-side analysis and retrospective
PET-MRI fusion was 79%/66%, 82%/100%, 86%/100% and 89%/100%, respectively. The overall sensitivity/specificity for
nodal staging on a patient basis for MRI, PET, side-by-side analysis and PET-MRI fusion was 94%/64%, 94%/91%, 94%/
82% and 94%/82%, respectively. MRI, PET, side-by-side analysis and retrospective image fusion were associated with
correct diagnosis/over-staging/under-staging of N-staging in 70.4%/18.5%/11.1%, 81.5%/7.4%/11.1%, 81.5%/11.1%/7.4%
and 81.5%/11.1%/7.4%, respectively.
ROC analysis showed no significant differences in tumor detection between the investigated methods. The Area Under
the Curve (AUC) for MRI, PET, side-by-side analysis and retrospective PET-MRI fusion were 0.667/0.667/0.702/0.708
(p > 0.05). The most reliable technique in detection of cervical lymph node metastases was PET imaging (AUC: 0.95),
followed by side-by-side analysis and retrospective image fusion technique (AUC: 0.941), which however, was not
significantly better then the MRI (AUC 0.935; p > 0.05).
Conclusions: We found a beneficial use of multimodal imaging, compared with MRI or PET imaging alone, particular
in individual cases of recurrent tumour disease. Side-by-side analysis and retrospective image fusion analysis did not
perform significantly differently.
Keywords: Multimodal imaging, PET-MRI fusion, Retrospective image fusion, Side-by-side analysis, Head-and-neck
cancer, StagingBackground
Clinical examination and imaging is routinely performed
for the staging of head-and-neck cancer (HNC) in order
to establish the tumour extent and size, to assess nodal
involvement, to evaluate detailed tumour spread, e.g.
bone infiltration and perineural infiltration, and to iden-
tify distant metastasis [1]. Accurate imaging is essential* Correspondence: loeffelbein@mkg.med.tum.de
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article, unless otherwise stated.for staging, treatment planning and follow-up, since sur-
gical intervention and neo- or adjuvant therapy modal-
ities depend on the outcome of the diagnostic results
[2]. For head-and-neck tumours, magnetic resonance
imaging (MRI) and computed tomography (CT) provide
accurate anatomical information with good resolution
but have well-known limitations, especially in the staging
of the nodal involvement of the neck [3,4] and recurrent
disease [5,6]. Furthermore, the differentiation between
malignant bone infiltration and infectious bone reaction
is also of poor accuracy [7]. An advantage of MRI is thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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which often interfere with CT interpretation [8].
Nowadays multimodal imaging by using positron emis-
sion tomography/computed tomography (PET/CT) has
gained a wide acceptance as a powerful imaging tool,
especially in recurrent tumour disease. The combination
of morphological and functional imaging (multimodal im-
aging) has been shown to reduce false positive or false
negative results [9,10]. Driven by the success of PET/CT
in HNC treatment [11,12], hybrid PET/MRI scanners are
now available to combine the high soft-tissue contrast
of MRI with the molecular and/or metabolic information of
PET. Previous reports have described the development of
reliable PET/MR imaging protocols [10,13-15] for HNC
staging. However, to date, only a few sequential or fully
integrated PET/MRI scanners are in clinical use. Most
departments can still only offer the use of the two
modalities (PET/CT and MRI) each as a single device.
The separately gained images can be additionally ana-
lysed in two different ways: 1) side-by-side analysis and
2) retrospective software-based image fusion. The latter
can be performed manually by shifting and rotating the
images by using landmarks as reference [16,17] or fully
automatically [18]. Retrospective image fusion is, be-
cause of its complexity, time-consuming, hardware-
and software-dependent and thus problematic in clinical
routine. Furthermore, differences in the patient’s position
during each imaging process limit the accuracy of the
retrospective fusion. On the other hand, this method has
been shown to lead to a more precise evaluation and treat-
ment of HNC in complex cases [14,19].
The purpose of this retrospective study was to assess
the clinical value of retrospective PET-MRI fusion and to
compare the diagnostic accuracy with side-by-side analysis
MRI and 18F-FDG PET alone.
Methods
Ethics statement
The study has been performed in accordance with the
Declaration of Helsinki and has been approved from an
ethical and legal point of view by the ethical committee
of the medical faculty of the Technische Universität
München (registration number: 366/14).
Patient population
Thirty-three patients (21 men and 12 women; age range
27–72 years; mean age 57 years) with primary malignant
neoplasm (n = 23), recurrent tumour disease (n = 6) and
lymph node metastasis in the framework of CUP (cancer
of unknown primary) (n = 4) in the head-and-neck region
were included in the study. All patients underwent clinic-
ally indicated preoperative contrast-enhanced MR imaging
and 18F-FDG PET/CT imaging within 14 days (mean three
days).The suspicious lesions/tumours were localised in the
oropharynx (n = 5), tongue (n = 5), floor of the mouth
(n = 4), hypopharnyx (n = 4), buccal mucosa (n = 2), val-
leculla (n = 1), tonsil (n = 1) and salivary gland (n = 1).
The recurrent tumours were localised in the floor of
the mouth (n = 2), tongue (n = 1), parotid gland (n = 1),
tonsil (n = 1) and oropharynx (n = 1) (Table 1).
Surgical treatment included the resection of the
tumour and uni- or bilateral neck dissection in 28 cases.
In five cases with recurrent tumour disease, only the
tumour was resected.
18F-FDG PET/CT imaging
PET/CT imaging was performed by using a Siemens
Biograph Sensation 64 PET/CT scanner (Siemens
Healthcare, Erlangen, Germany) equipped with lutetium
oxy-orthosilicate (LSO) crystals. The spatial resolution
was 4.4 mm at 1 cm and 5.0 mm at 10 cm from the centre
of the transverse FOV (field of view) and the sensitivity
was 8.1 kcps/MBq at the centre of the FOV. After at least
four hours of fasting, the patients received a weight-
dependent intravenous injection of 350–500 MBq of 18F-
FDG. Blood glucose levels were checked in all patients,
before injection, to be below 150 mg/dl. For attenuation-
correction purposes and anatomical correlation, a low-
dose CT scan (120 keV, 20 mAs, no i.v.-contrast) was
acquired in shallow expiration. When clinically indicated,
a diagnostic CT (120 kV, 240 mAs, 0.5 s per rotation,
5 mm slice thickness, portal venous phase 80 s after the
injection of 80–120 ml i.v. contrast agent [Imeron 300])
was performed. In patients with a diagnostic CT scan, this
scan was used for attenuation correction.
PET scan was performed immediately after CT, with a
3-min acquisition per bed position (6–8), by using a
three-dimensional acquisition mode.
MR imaging
Patients underwent MRI in a Magnetom Verio 3 Tesla
MRI Scanner (Siemens Medical Solutions, Erlangen,
Germany). We obtained unenhanced axial T1-weighted
images, enhanced axial T1-weighted and coronal T1-
weighted fat-saturated images after gadolinium DTPA
injection (Gadolinium-DTPA 0,1 mmol/kg body weight)
and T2-weighted fat-suppressed fast-spin-echo (T2-STIR-
sequence) images in axial, sagittal and coronal planes in
all patients.
Data processing and retrospective PET-MR image fusion
All attenuation-corrected PET and enhanced T1-weighted
MRI series were retrospectively fused by using a commer-
cially available software program (3D Fusion, Siemens
Medical Solutions, Erlangen, Germany) on a separate
Siemens Workstation (Syngo MMWP, Siemens Medical
Solutions, Erlangen, Germany). The software allows
Table 1 Demographic data of the thirty-three enrolled patients, information concerning tumour location and
study-relevant information as an overview
Case Location of tumour site Time between MRT and PET (d) Indication Histopathological result TNM classification
1 Tonsil 7 Primary staging SCC pT2 pN2b pMx
2 CUP/Tonsil 7 Primary staging SCC pT1 pN1 pMx
3 Oropharynx 1 Recurrent tumour Chronic inflammation -
4 CUP 3 Primary staging SCC cTx pN2b pMx
5 Tongue 0 Primary staging SCC pT2 pN2c pMx
6 Parotid Gland 8 Primary staging SCC pT3 pN2c pMx
7 Oropharynx 14 Primary staging SCC pT2 pN0 pMx
8 Oropharynx 6 Primary staging SCC pT4b pN2b pMx
9 Buccal mucosa 2 Primary staging SCC pT1 pN2b pMx
10 Hypopharynx 6 Primary staging SCC pT1 pN1 pMx
11 Tongue 14 Recurrent tumour SCC rpT2 pNx pMx
12 Parotid Gland 1 Recurrent tumour Adenoid cystic Carcinoma rpT1 pNx pMx
13 Floor of the mouth 1 Primary staging SCC pT1 pN0 pMx
14 Tongue 0 Primary staging SCC pT1 pN0 pMx
15 Oropharynx 1 Primary staging SCC pT1 pN2a pMx
16 Oropharynx 0 Primary staging SCC pT3 pN2b pMx
17 Tongue 0 Primary staging SCC pT3 pN2b pMx
18 Hypopharynx 0 Primary staging SCC pT3 pN2a pMx
19 Tongue 0 Primary staging SCC pT1 pN0 pMx
20 Floor of the mouth 0 Primary staging SCC pT1 pN0 pMx
21 Floor of the mouth 0 Primary staging SCC pT1 pN0 pMx
22 Floor of the mouth 0 Primary staging SCC pT2 pN0 pMx
23 Hypopharynx 0 Primary staging SCC pT2 pN2b pMx
24 Oropharynx 0 Primary staging SCC pT3 pN2b pMx
25 Buccal mucosa 1 Primary staging Fibroxanthoma -
26 Floor of the mouth 6 Metachronous tumour SCC pT2 pN0 pMx
27 Floor of the mouth 6 Recurrent tumour SCC rpT2 pNx pMx
28 CUP 5 Primary staging SCC cTx pN2b pMx
29 Tongue 0 Primary staging SCC pT2 pN0 pMx
30 CUP 8 Primary staging SCC cTx pN2b pMx
31 Tonsil 1 Recurrent tumour Fibrosis -
32 Hypopharynx 3 Primary staging SCC pT2 pN2b pMx
33 Vallecula 6 Primary staging SCC pT1 pN0 pMx
Abbreviations: M: man; W: woman; CUP: cancer of unknown primary; SCC: squamous cell carcinoma; TNM: tumour classification according to Weber et al.
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phical imaging modalities (datasets) acquired at different
time points. After initial loading of the MR dataset in the
3D card, the PET dataset was included using the fusion
tool. Hereby, a first initial orientation manual alignment
has to be performed in order to roughly match prominent
anatomical landmarks (cerebellum, spine tonsils) of the
two datasets. After that, the software automatically aligns
the two datasets (MR and PET) based on mutual informa-
tion using the anatomical contours of the loaded datasets(e.g. head, neck etc.). Lastly, fused images were examined
and - if necessary - manually fine adjusted for correct
alignment by using landmarks such as the cerebellum, the
tonsils, the vocal cords and the spine.
Image analysis
Two observers, namely an experienced head-and-neck im-
aging radiologist and an experienced nuclear medicine
physician, retrospectively reviewed all 33 image sets of the
enrolled patients independently. According to a structured
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tumour was benign or malignant, tumour localisation,
bone infiltration (T-staging) and metastases to cervical
lymph nodes (N-staging) by using a five-point-scaling
system: 1 =most likely benign, 2 = probably benign,
3 = equivocal/indeterminate, 4 = probably malignant and
5 =most likely malignant.
Metastases to locoregional lymph nodes were analysed
separately with regard to the ipsi- or contralateral side
and the presence of metastases was recorded according
to the classification described by Robins et al. [20]. In an
attempt to imitate a normal clinical set-up, none of the
observers was aware of the histopathological findings or
follow-up but was fully informed of the clinical history
and actual clinical findings of the patients.
In the analysis of MRI, the primary tumour was assessed
for loss of symmetry, tissue shifting, abnormal tissue en-
hancement, inhomogeneity in tissue architecture, bony in-
filtration or other infiltration of neighbouring structures
and abnormal focal-contrast enhancement (T-staging). A
lymph node was considered as positive for metastasis if
the short-axis axial diameter was >10 mm. If lymph nodes
were smaller than 10 mm but showed signs of central ne-
crosis and rim contrast enhancement, extra-capsular ex-
tension or obliteration of surrounding fat planes, they
were also counted as positive neck nodes (N-staging).
The analysis of the PET images was performed visu-
ally. The corresponding CT images were only used for
anatomical orientation and were not analysed separately
or as PET/CT. For the visual analysis all PET images
were scaled at a SUV (standardised uptake value) of five.
All non-physiological focally increased 18F-FDG uptake
in the head-and-neck region were analysed in detail, ac-
cording to the five-point-scaling system (see above).
After the separate analysis of PET and MR images,
both observers reviewed the imaging data concurrently
in a side-by-side fashion on two adjacent screens. Both
observers had to agree to a mutual score with regard to
T-staging (including bone infiltration) and N-staging ac-
cording to the five-point-scaling system.
In the third assessment round, both observers analysed
the fused PET-MR images and had to again agree to a mu-
tual score regarding the T-staging (including bone infiltra-
tion) and N-staging according to the five-point-scaling
system.
Histopathological reference
The type and extent of surgical resection of the tumour
and the type of the neck dissection was determined by
our head-and-neck surgical team on the basis of staging
results and estimated risk of occult metastases [21]. An
experienced anatomical pathologist performed the histo-
pathological evaluation of the resected tissue. The as-
sessment was based on the TNM-classification systempresented by Weber et al. [22]. All patients were rated as
Mx as the M-status had no influence on the study design
and analysis. Bony infiltration was analysed by direct
histological evaluation of the resected bone. If no bone
resection was performed and/or the soft tissue specimen
next to the tumour was rated as R0, the adjacent bony
structures next to the tumour were also rated as being
not infiltrated.
Statistical analysis
The results of the histopathological evaluation were corre-
lated with the diagnostic graduation of MRI, PET, side-by-
side analysis and retrospective PET-MR image fusion by
using receiver operating characteristic (ROC) curve in
combination with Area Under the Curve (AUC). For this
analysis the scores of the five-point-scaling system were
binary-coded (1–3 were rated as benign and 4–5 were
rated as malignant). The binary score of the different im-
aging techniques and the histopathological analysis of spe-
cimen were used as variables.
The Youden-Index was used to determine the cut-off
point at which both tumor and lymph node involvement
scores had the highest correlation with the histopatho-
logical specimen.
Correct positive, false positive, correct negative and false
negative rates were calculated and the sensitivity and spe-
cificity were determined for T-staging and N-staging. With
regard to N-staging, differentiation between positive (N+)
and negative (N0) cervical lymph nodes was performed at
the patient level. Because of the low patient count, we
could not differentiate between primary or recurrent
tumour diseases or between CUP syndromes.
The data was analyzed with the “Statistical Package for
the Social Sciences” (SPSS for Windows, release 21.0.0.
2013, SPSS Inc). The figures were generated with SPSS.
Results
Technique of image fusion
The semi-automatically image registration with manually
adjustment for correct alignment took about 10–20 mi-
nutes per case before the analysis started. PET-MRI fu-
sions could be performed in all cases with no obvious
limitations, even though fine manual readjustments had
to be done in some cases after automatic fusion was
completed.
Results of T-staging
Thirty-one (n = 31) suspected tumour lesions were consid-
ered for analysis, since, in one patient of the four CUP
syndrome cases, a primary tumour had been detected in
the tonsil (case 2). In case 26, an additional metachronous
tumour became evident in the analysis and was also
accounted for the following analysis. Malignant tumours
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in nature.
The overall sensitivity and specificity of T-staging for
MRI, PET, side-by-side analysis and PET-MRI fusion are
presented in Table 2.
Out of the seven falsely rated MRI analyses, one be-
nign lesion was falsely rated as malignant and six malig-
nant lesions were falsely rated as benign. Therefore, MRI
alone was associated with a positive predictive value of
96% and a negative predictive value of 25%.
In the analysis of PET alone, five actually malignant le-
sions were falsely rated as benign. Out of these, three le-
sions had not been detected and two moderately increased
up-takes were rated as nonspecific activity. Therefore,
PET alone was associated with a positive predictive value
of 100% and a negative predictive value of 38%.
In the simultaneous analysis of MRI and PET in a
side-by-side fashion, two additional malignant lesions
than in MRI alone were detected and one suspicion of
malignancy was rejected. Side-by-side analysis was asso-
ciated with a positive predictive value of 100% and a
negative predictive value of 43%.
The analysis of retrospectively fused PET-MR images
detected one additional malignancy in a case after tongue
reconstruction. Because of the altered anatomical struc-
tures, MRI alone was rated as “indeterminate”, whereas in
the side-by-side analysis, it was rated as probably benign,
with only the evaluation of the fused images confirming
the malignancy of the suspicious lesion. Retrospective
PET-MRI fusion was associated with a positive predictive
value of 100% and a negative predictive value of 50%.
However, three malignant tumours remained un-
detected in all evaluation rounds. One small tumour of
the oropharynx (pT1) and one tumour of the buccal mu-
cosa (pT1) were not seen at all. One carcinoma in situ
of the left tonsil was rated as 2 = probably benign in
MRI and as 1 =most likely benign in PET/CT and in
side-by-side analysis and image fusion. Biopsy by panen-
doscopy revealed these three tumours histologically.
As a summary statistic the ROC-curve is illustrated in
Figure 1. The cut-off point for the different methods in-
vestigating tumor evidence was at a score of 3.5 in all










MRI 79% (22/28) 66% (2/3) 96% (22/23) 25% (2/8)
PET 82% (23/28) 100% (3/3) 100% (23/23) 38% (3/8)
side-by-side 86% (24/28) 100% (3/3) 100% (24/24) 43% (3/7)
PET-MRI Fusion 89% (25/28) 100% (3/3) 100% (25/25) 50% (3/6)(AUC: 0.708, Youden-Index: 0.524) was the most reliable
technique, followed by side-by-side analysis (AUC: 0.702,
Youden-Index: 0.488) and both the MRI and PET imaging
(AUC: 0.667, Youden-Index: 0.453). There were no signifi-
cant differences in tumor detection between the investi-
gated methods (p > 0.05).
The analysis of mandibular bone infiltration was im-
paired in single case because of susceptibility artefacts in
MRI (n = 2) or because of motion artefacts (n = 1). In
PET/CT imaging, the analysis of potentially involved
bone was complicated by beam-hardening artefacts in
four cases (n = 4), caused by metallic implants. In two
out of 28 malignant tumour resections, bony infiltration
was established in histological work-up. MRI and PET
analysis alone were each able to detect these bone infiltra-
tions but were also associated with one false positive diag-
nosis each in other cases. Finally, the PET-MRI fusion was
able to exclude bone infiltration by matching the suspi-
cious tracer uptake of the PET-scan to the soft tissue
tumour site next to the bone and not to the probably peri-
odontal inflamed mandible. In the side-by-side analysis,
this case was also rated as “probably infiltrated” because of
insufficient virtual matching of the two modalities.
Results of N-staging
In total, twenty-seven cases (27/33) were analysed for
lymph node metastases to the neck (N-staging). No neck
dissection had been performed in five cases of recurrent
tumour disease and in one case of fibroxanthoma. Histo-
pathological specimens showed metastases to the cervical
lymph nodes (N+) in 16 patients, whereas eleven cases
were free of metastases to cervical lymph nodes (N0).
The overall sensitivity and specificity of N-staging on a
“per patient” basis for MRI, PET, side-by-side analysis
and PET-MRI fusion is represented in Table 3.
In the analysis of MRI or PET data alone, 15 out of 16
cases were correctly diagnosed with metastatic spread to
the cervical lymph nodes. MRI analysis alone detected
seven N0 necks (7/11) correctly; PET detected ten N0
necks (10/11) correctly. Therefore, MRI and PET analysis
alone were associated with a positive predictive value of
79% and 94% and a negative predictive value of 88% and
91%, respectively.
In side-by-side analysis of MRI and PET data, two
more N0 necks were detected than in MRI alone. In the
first case, a missing increased up-take of 18F-FDG in
MRI-diagnosed enlarged lymph nodes led to the correct
diagnosis. In another case, an “unsure increased up-
take” of 18F-FDG led to the wrong PET-diagnosis but
could be overruled by a clear MRI diagnosis of non-
pathological lymph nodes. The side-by-side analysis de-
tected nine N0 necks (9/11) correctly and was associated
with a positive and negative predictive value of 88% and
90%.
Figure 1 ROC-curves to compare the accuracy of the different techniques for detection of malignant lesions.
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sults as the side-by-side analysis.
On an N-staging basis, MRI, PET, side-by-side analysis
and retrospective image fusion were associated with
the displayed correct diagnosis/over-staging/under-staging
rates in Table 4. All pathological malign lymph nodes that
were not detected by imaging had a maximal diameter
smaller than 10 mm.
The ROC-curve is illustrating the performance of all im-
aging modalities in detection of lymph node metastases to
the neck as a summary statistic (Figure 2). The cut-off point
for the different methods investigating lymph node evi-
dence was at a score of 4.5 in all methods described. The
most reliable technique was PET imaging (Youden-Index:
0.882, AUC: 0.95), directly followed by side-by-side analysis
and retrospective image fusion technique (Youden-IndexTable 3 Diagnostic results of nodal staging of the neck
(N-staging) in twenty-seven patients on a “per patient”









MRI 94% (15/16) 64% (7/11) 79% (15/19) 88% (7/8)
PET 94% (15/16) 91% (10/11) 94% (15/16) 91% (10/11)
Side by Side 94% (15/16) 82% (9/11) 88% (15/17) 90% (9/10)
Fusion 94% (15/16) 82% (9/11) 88% (15/17) 90% (9/10)each: 0.882, AUC: 0.941), which however, were not signifi-
cantly better then the MRI (Youden-Index each: 0.882,
AUC 0.935; p > 0.05).
Discussion
In order to determine the clinical benefit of PET-MRI fu-
sion in HNC, we have analysed the value of retrospective
PET-MRI fusion and compared the results with side-by-
side analysis and PET or MRI alone. Although in our
small patient population no statistically significant differ-
ences in the performance of each technique could be de-
termined for local tumour assessment or lymph node
staging, there was a trend towards a better performance of
multimodal imaging (side by side analysis or retrospective
image fusion) especially in the diagnosis of recurrent
HNC and inconclusive findings in the single modality.
Based on these data, this finding now has to be confirmed
in larger prospective studies.
To our knowledge, no previous study has compared the
value between retrospective image fusion and side-by-side
analysis up to now. A diagnostic benefit has to be proven
for multimodal imaging, since morphological imaging by
using MRI or CT alone has nowadays reached a high ac-
curacy in patient follow-up and even allows the detailed
analysis of structures such as mucosal invasion [3,23]. Ac-
curate assessment of the local tumour extent is important
for the surgeon, as the imaging results will determine the
Table 4 Diagnostic results of nodal staging of the neck (N-staging) in twenty-seven patients by using MRI, PET/CT,
side-by-side analysis and retrospective PET-MRI fusion as clinical N-staging with imaging (cN) and correlation to the
histopathological results (pN)
MRI PET/CT Side-by-side/PET-MRI Fusion
cN0 cN1 cN2a cN2b cN2c cN0 cN1 cN2a cN2b cN2c cN0 cN1 cN2a cN2b cN2c
pN0 7 1 0 1 2 pN0 10 1 0 0 0 pN0 9 2 0 0 0
pN1 0 2 0 0 0 pN1 0 2 0 0 0 pN1 0 2 0 0 0
pN2a 0 0 2 0 0 pN2a 0 0 2 0 0 pN2a 0 0 2 0 0
pN2b 1 1 0 7 1 pN2b 1 2 0 6 1 pN2b 1 1 0 7 1
pN2c 0 1 0 0 1 pN2c 0 0 0 0 2 pN2c 0 0 0 0 2
Correct staging: 70.4% Correct staging: 81.5% Correct staging: 81.5%
Over-staging: 18.5% Over-staging: 7.4% Over-staging: 11.1%
Under-staging: 11.1% Under-staging: 11.1% Under-staging: 7.4%
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the adjuvant therapy.
In several studies, the beneficial use of PET data in
primary T-staging has been reported [24,25] and has led
to the assumption that PET and MRI analysis further
complement each other [6,15]. In our study, one false
negative and one false positive rating in MRI could be
changed to the correct diagnosis through side-by-side
analysis and elevated the sensitivity/specificity to 85%/
100%. Retrospective image fusion had the highest sensi-
tivity/specificity rates in T-staging of 89%/100%. It wasFigure 2 ROC-curves to compare the accuracy of the different techniqshown to be of evident value in a suspected recurrent
tumour (Figure 3). As is well-known, morphological im-
aging alone (MRI or CT) in previously operated regions is
challenging due to sometimes difficult differentiation be-
tween non-neoplastic and neoplastic change. The reasons
are scar tissue, loss of symmetry, side shift and unspecific
contrast enhancement [5]. PET has gained wide accept-
ance in staging of suspected recurrent tumour disease, be-
cause of its high negative predictive values of up to 95%.
On the other hand, it is also associated with false positive
findings shortly after operation and should therefore beues for detection of cervical lymph node metastases.
Figure 3 Beneficial use of retrospective image fusion in a case of recurrent tumour disease. The presented case (no. 27, rpT2 pNx pMx)
has suspected recurrent disease after resection of a squamous cell carcinoma of the floor of the mouth and tongue and reconstruction with a
microvascular radial forearm flap and adjuvant radiation. A: The tissue by MRI alone was rated as probably malign, attributable to the abnormal
contrast enhancement in the right posterior site of the floor of the mouth (red arrow). The region near the midline of the residual tongue (white
arrow) was interpreted as an anatomical alteration after surgery and irradiation. B: PET alone showed a moderate increase of tracer up-take near
the midline and both PET alone and the side-by-side analysis were rated as “probably benign”. C: Retrospective image fusion provided the correct
diagnosis of recurrent tumour disease through the correct alignment of morphological and functional imaging data; however, the disease was
present not in the dorso-lateral region (histology: scar fibrosis) but near the midline in the residual tongue (histology: SCC recurrent disease).
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time interval of 10–12 weeks after surgery [26-28].
In our analysis, retrospective PET-MRI fusion in initial
tumour staging of primary lesions was of minor advan-
tage compared with a single modality or to the side-by-
side analysis with regard to T-staging. No significant
benefit of retrospective image fusion was seen compared
with side-by-side analysis. However, multimodal imaging
(fusion and side-by-side analysis) had a tendency for
higher sensitivity compared to MRI or PET alone, al-
though the difference was not significant.
Another important aspect of HNC staging is the rec-
ognition of tumour invasion of neighbouring structures,
such as maxilla or mandible. As described earlier, add-
itional PET data might be beneficial in the detection of
bone infiltration compared with MR images alone [29].
In one case of our present study, retrospective PET-MRI
fusion could also reduce false positive diagnoses for
bone infiltration and correspondingly could reduce sur-
gical over-treatment.
Staging for metastases to cervical lymph nodes (N-
staging) plays an important role and correlates directly
with the survival of the patient [30,31]. Correct diagno-
ses are still associated with difficulties, especially when
only morphological imaging technique is performed [32].
The reported sensitivity/specificity ranges between 78-
88%/75-86% for MRI alone [4,33]. The differentiation be-
tween benign and malignant lymph node enlargement in
morphological imaging alone (CT or MRI) mainly relies
on size-based evaluation. However, the sizes of lymph
nodes, whether benign or malignant, vary and previously
studies have shown that up to 21% of nodes smaller than
10 mm can be malignant and up to 40% of nodes larger
than 10 mm can be benign [32,34]. Our high sensitivity
for MRI (94%) can be explained by only differentiatingbetween N0 or N+ staging and no node-by-node compari-
son. PET/CT is able to raise the specificity up to 97% but
is still accompanied with a low sensitivity of 50-84%
[33,34]. In our results, PET analysis alone achieved the
highest sensitivity and specificity rates (94% and 91%) and
was higher than that reported in the literature. Our small
patient population might well be the reason for these
findings.
On a “N-staging per patient basis”, MRI only achieved
correct staging in 70.4%, whereas PET alone, side-by-side
analysis and PET-MRI fusion achieved correct staging in
81.5% (Table 4). Furthermore, side-by-side analysis and
retrospective image fusion achieved the lowest under-
staging rates compared with PET and MRI alone (7.4% vs.
11.1%). On the other hand, MRI had the highest rates of
over-staging (18.5%) compared with multimodal imaging
(11.1%). Both retrospective image fusion and side-by-side
analysis corrected two initial false positive ratings to N0
staging. PET analysis alone was associated with the lowest
rate of over-staging (7.4%). As shown in our results, even
with retrospective PET-MRI fusion or side-by-side analysis,
malignant neck lymph nodes smaller than 10 mm remained
undetected and were associated with a lower specificity
than by PET analysis alone (82% vs. 91%), as caused by the
false positive influence of the MRI. Ng et al. also reported a
superiority of PET analysis for nodal staging compared with
MRI alone. By analysing the nodal status in a side-by-side
fashion, they showed a trend of increased diagnostic accur-
acy over the single modalities [35].
Our study has some limitations. The main limitations
are its retrospective design, the inhomogeneous patient
population including patients with primary and recur-
rent disease and the relatively small number of patients
included. However, these limitations do not decisively
influence the results of our study. As the observers were
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nature of the study should not have influenced the diag-
nostic performance of image fusion. Furthermore, the
aim of our study was to evaluate performance of image
fusion of PET and MRI in the head and neck region. We
therefore chose to include patients with diseases in this
region, independently of the primary or the recurrent
disease. Despite the relatively small number of patients
included in the study, our results confirmed the known
superiority of combining morphological and functional
imaging in diagnostic accuracy. However there were no
beneficial gains for the image fusion in this aspect com-
pared to side-by-side analysis.
In summary, we found positive trends of multimodal
imaging in T- and N-staging of HNC cancer. Nevertheless,
the proof of cost-effectiveness of an initial multimodal im-
aging (PET/CT or PET/MRI) for primary staging of HNC
and also any evident and significant advantages in diagno-
ses of bone infiltration are still pending and must be ana-
lysed systematically. Another question to be answered is,
whether it is contemporary to perform time consuming
and in some cases difficult retrospective image fusion or
side-by-side analysis when it is possible to use fully inte-
grated PET/MRI scanners in primary staging of HNC.Conclusion
Our study has shown the beneficial use of multimodal im-
aging by using retrospective PET-MRI fusion in selected
HNC cases only. Compared with morphological MRI
alone, we have seen advantages in single cases of recurrent
diseases and in the ambiguous diagnosis of suspected
lymphatic spread to the neck. However, the complex and
time-consuming nature of retrospective image fusion
hardly justifies the routine use in light of the only slight
advantages compared to side-by-side analysis. However
this technical limitation can be overcome by fully inte-
grated PET/MRI scanners, which have recently become
available. Their clinical value for HNC has not as yet been
fully defined [14,36,37] and must be analysed systematic-
ally in future studies.
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